Table 2.
Prevalence of HIV drug resistance detected by SS and NGS.
| SS | 20% NGS a | 15% NGS a | 10% NGS a | 5% NGS a | 2% NGS a | 1% NGS a | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SS or NGS at Various Thresholds | N (%) | N (%) | p Value | N (%) | p Value | N (%) | p Value | N (%) | p Value | N (%) | p Value | N (%) | p Value |
| Any classes | 34 (19.5) | 36 (20.7) | 0.317 | 36 (20.7) | 0.317 | 37 (21.3) | 0.180 | 42 (24.1) | 0.011 | 79 (45.4) | <0.001 | 139 (79.9) | <0.001 |
| PI-related | 1 (0.6) | 1 (0.6) | 1.000 | 1 (0.6) | 1.000 | 2 (1.2) | 0.317 | 5 (2.9) | 0.046 | 9 (5.2) | 0.005 | 23 (13.2) | <0.001 |
| NRTI-related | 1 (0.6) | 1 (0.6) | 1.000 | 1 (0.6) | 1.000 | 1 (0.6) | 1.000 | 3 (1.7) | 0.157 | 43 (24.7) | <0.001 | 120 (69.0) | <0.001 |
| NNRTI-related | 33 (19.0) | 35 (20.1) | 0.317 | 35 (20.1) | 0.317 | 35 (20.1) | 0.317 | 36 (20.7) | 0.180 | 43 (24.7) | 0.004 | 51 (29.3) | <0.001 |
| EFV/NVP | 27 (15.5) | 28 (16.1) | 0.564 | 28 (16.1) | 0.564 | 29 (16.7) | 0.317 | 31 (17.8) | 0.103 | 37 (21.3) | 0.004 | 46 (26.4) | <0.001 |
SS, Sanger sequencing; a NGS, next-generation sequencing at 1%, 2%, 5%, 10%, 15%, or 20% detection thresholds; PI, Protease inhibitor; NRTI, Nucleoside reverse-transcriptase inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor.